Cargando…
Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
BACKGROUND: Successful treatment of solid tumors relies on the ability of drugs to penetrate into the tumor tissue. METHODS: We examined the correlation of panitumumab (an anti-epidermal growth factor [EGFR] antibody) tumor penetration and EGFR saturation, a potential obstacle in large molecule drug...
Autores principales: | Freeman, Daniel J, McDorman, Kevin, Ogbagabriel, Selam, Kozlosky, Carl, Yang, Bing-Bing, Doshi, Sameer, Perez-Ruxio, Juan Jose, Fanslow, William, Starnes, Charlie, Radinsky, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499177/ https://www.ncbi.nlm.nih.gov/pubmed/22830443 http://dx.doi.org/10.1186/1476-4598-11-47 |
Ejemplares similares
-
Immunogenicity of panitumumab in combination chemotherapy clinical trials
por: Weeraratne, Dohan, et al.
Publicado: (2011) -
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Hoda, Daanish, et al.
Publicado: (2008) -
Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Williams, Kerry J, et al.
Publicado: (2009) -
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
por: Braig, Friederike, et al.
Publicado: (2015) -
Clinical Pharmacokinetics and Pharmacodynamics of the Epidermal Growth Factor Receptor Inhibitor Panitumumab in the Treatment of Colorectal Cancer
por: Ketzer, Sander, et al.
Publicado: (2017)